Results 111 to 120 of about 21,169 (256)

Oligoprogressive renal cell carcinoma: What is the role of surgery?

BJU International, EarlyView.
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart   +9 more
wiley   +1 more source

Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy [PDF]

, 2017
Background Postoperative adjuvant radiation therapy (ART) in T3 and R1 prostate cancer as well as salvage radiation therapy (SRT) in case of postoperative biochemical failure (BF) are established treatments.
Barelkowski, Tomasz, Beck, Marcus, Budach, Volker, Ghadjar, Pirus, Kaul, David, Thieme, Alexander-Henry, Wecker, Sascha, Wlodarczyk, Waldemar, Wust, Peter   +8 more
core   +1 more source

Nodal maximum standardised uptake value improves PSMA‐PET/CT‐based nodal staging in intermediate‐ and high‐risk prostate cancer

BJU International, EarlyView.
Objectives To evaluate whether nodal maximum standardised uptake value (SUVmax) improves the positive predictive value (PPV) of prostate‐specific membrane antigen (PSMA) positron emission tomography (PET)/computerised tomography (CT) for detecting lymph node invasion (LNI) in prostate cancer (PCa), and to develop clinical decision tools to guide ...
Alexandra S. Bruins Slot, Vera Sweere, Joris G. Heetman, Rick Hermsen, Lieke Wever, Jules Lavalaye, Maarten Vinken, Clinton D. Bahler, Mark Tann, Claudia Kesch, Tugce Telli, Wolfgang P. Fendler, Peter Ka‐Fung Chiu, Kwan Kit Wu, Fabio Zattoni, Laura Evangelista, Francesco Ceci, Marcin Miszczyk, Pawel Rajwa, Akihiro Matsukawa, Tamás Fazekas, Francesco Barletta, Alberto Briganti, Francesco Montorsi, Giorgio Gandaglia, Jean‐Paul A. Van Basten, Harm H. E. Van Melick, Roderick C. N. Van den Bergh, Giancarlo Marra, Timo F. W. Soeterik, Matthijs J. V. Scheltema, on behalf of the European Association of Urology‐Young Academic Urologists (EAU‐YAU) Prostate Cancer Working Group   +31 more
wiley   +1 more source

Expert consensus on clinical application of 177Lu-prostate specific membrane antigen radio-ligand therapy in prostate cancer

Zhongguo Linchuang Yixue
177Lu- prostate specific membrane antigen (PSMA) radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China.
Guobing LIU, Weihai ZHUO, Yushen GU, Zhi YANG, Yue CHEN, Wei FAN, Jianming GUO, Jian TAN, Xiaohua ZHU, Li HUO, Xiaoli LAN, Biao LI, Weibing MIAO, Shaoli SONG, Hao XU, Rong TIAN, Quanyong LUO, Feng WANG, Xuemei WANG, Aimin YANG, Dong DAI, Zhiyong DENG, Jinhua ZHAO, Xiaoliang CHEN, Yan FAN, Zairong GAO, Xingmin HAN, Ningyi JIANG, Anren KUANG, Yansong LIN, Fugeng LIU, Cen LOU, Xinhui SU, Lijun TANG, Hui WANG, Xinlu WANG, Fuzhou YANG, Hui YANG, Xinming ZHAO, Bo YANG, Xiaodong HUANG, Jiliang CHEN, Sijin LI, Jing WANG, Yaming LI, Hongcheng SHI   +45 more
doaj   +1 more source

Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy

Cancer Science, EarlyView.
Early screening for somatic alterations in localized prostate cancer could help predict biochemical recurrence risk and optimize salvage therapy selection. ABSTRACT The clinical significance of comprehensive genomic profiling (CGP) has been established in metastatic castration‐resistant prostate cancer (PC).
Kenji Zennami, Tetsuya Takimoto, Takuhisa Nukaya, Makoto Sumitomo, Mayu Takeda, Eiji Sugihara, Hideyuki Saya, Ryoichi Shiroki   +7 more
wiley   +1 more source

Intense fluoro-2-deoxyglucose uptake in high-grade prostatic adenocarcinoma with negligible prostate-specific membrane antigen expression

Urology Annals, 2019
While 68Gallium prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA) has demonstrated increasing utility in the evaluation of prostatic carcinoma, it is essential to be aware of false-negative findings.
Tansel Cakir, Selcuk Guven, Bahar Muezzinoglu, Cengiz Erol, Mustafa Yucel Boz, Tamer Atasever   +5 more
doaj   +1 more source

Expression von Prostate-specific membrane antigen (PSMA) beim papillären Nierenzellkarzinom (pNZK)

, 2019
65.
Zschäbitz, S, Erlmeier, F, Stöhr, C, Polifka, I, Schrader, AJ, Hartmann, A, Ivanyi, P, Steffens, S   +7 more
openaire   +2 more sources

A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA)

Oncotarget, 2011
We have developed a modular scaffold for preparing high-affinity, homo-multivalent inhibitors of the prostate-specific membrane antigen (PSMA) for imaging and therapy of prostate cancer (PCa). Our system contains a lysine-based (µ-, e-) dialkyne residue for incorporating a PSMA binding Lys-Glu urea motif exploiting click chemistry and a second lysine ...
Sangeeta Ray, Banerjee, Mrudula, Pullambhatla, Hassan, Shallal, Ala, Lisok, Ronnie C, Mease, Martin G, Pomper   +5 more
openaire   +3 more sources

A Pilot Study of 18F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease

The Prostate, Volume 86, Issue 8, Page 865-871, June 2026.
ABSTRACT Introduction PSMA‐PET offers an opportunity to reduce the mischaracterization of disease in active surveillance (AS) and focal therapy (FT) candidates. We describe the results of a pilot clinical trial evaluating 18F‐radiohybrid(rh)PSMA‐7.3‐PET/MRI to detect occult adverse pathology among potential AS and FT candidates (NCT05852041).
Ridwan Alam, Derek Hesse, Nikki Hubbard, Emma McGarrity, Sai Kumar, Clayton Neill, Yutai Li, Nicole Handa, Hiten D. Patel, Edward M. Schaeffer, Hatice Savas, Ashley E. Ross   +11 more
wiley   +1 more source

Prostate-specific membrane antigen (PSMA) PET-CT guided radiotherapy in oligometastatic prostate cancer.

Journal of Clinical Oncology, 2017
213 Background: Metastases-directed therapy by metastasectomy or radiotherapy (RT) might delay disease progression and postpone systemic treatment in patients with oligometastatic prostate cancer. Here, we evaluated retrospectively the efficacy and toxicity of 68Ga prostate-specific membrane antigen (PSMA) PET-CT guided radiotherapy (RT) in the ...
Engels, Benedikt, Guler, Ozan Cem, Onal, Cem, De Ridder, Mark   +3 more
openaire   +3 more sources